REGRIGGES OF PRESCRIENG INFORMATION
These highlights do not include all the information needed to use FOSAPSEPITANT FOR INECTION safely
and efficiency, See full prescribing information for FOSAPSEPITANT FOR INECTION.
FOSAPSEPITANT for injection, for intraversions use
Initial U.S. Appendix 1046 These basis for the control of the c Section 1. The continues of the continu A DENIES MATERIAL TO A STATE OF THE AMERICAN DISSISSATION OF THE AMERICAN DISSISSATION AND ASSISTANCE AS A STATE OF THE AMERICAN DISSISSATION AS THE AMERICAN DISSISSATION DISSISSATION AS THE AMERICAN DISSISSATION FULL PRESCRIBING INFORMATION | Chembray | 2 mg | 2 m \*Administration and the second section of the second section and the second section and se \*Administration of examenhancer 20 inframes prior to the members protestered on Day 1. A 20% dissage relate clean of formed became in recurrented by account for a deep time-cention with incorporate production of the company of the Publisher is an information in approach of for first VAMP, or Enhance Corp., a subsidiary of Morel & Ga., So. X. Tomed (Supersystem) for Septime Informer, dura to Morel Super & Dobne Corp., a subsidiary of Morel & Ga., No. X. Yandering, and developed by Orghe. A deep superior is not belief with the public subprission. Co., to 3 van besting scalaring region, the day guident new labels of the Apraham experiments.

3.4 Propagation for Septimal to Taylorina.

Table 5. Propagation for Septimal for Taylorina.

Table 5. Propagation for Septimal for Taylorina.

Table 5. Propagation for Septimal for Taylorina (SE) and Septimal for Septima In the Control of the

J DOSAGE FORMS AND STRENGTHS

Fourpreplant for injection: 150 mg fosupreplant, white to off white cake or powder insingle-dose glass vial for recommination.

glass vid for reconsistants

CONTRANDICATION

Floregorphism in contradicated in patients

Westings and Floregorphism of Exploregorphism in Contradicated (E.S.).

Maring patients, Malanticated (C.S.). Above the care consistent (E.S.).

Maring patients, Malanticated (C.S.). Above the care consistent contradicated (E.S.).

Maring patients, Malanticated (C.S.). Above the care consistent contradicated in contradicated (E.S.).

Maring patients, Malanticated (C.S.). Above the care consistent contradicated in contradicated (E.S.).

Maring patients, Malanticated (C.S.).

Maring patients, Malanticated (C.S.).

Maring patients, Malanticated (E.S.).

Maring patients.

set in CT pellocation, Interestation or content of parasitis how Wormings and
Personance, (2).

3 NARNING AND PRECENTION

3 NARNING AND PRECENTION

5 Chicking Supposed with The Content of CTVFAA, and exprises in
section of the Content of CtvFAA. The planting of CtvFAA and propries in
schools and admits and makes of CtvFAA and propries in
schools and admits and makes of CtvFAA. The planting of the CtvFAA and propries in
schools and admits and the CtvFAA and propries in
schools and the CtvFAA and propries in
schools and the CtvFAA and propries in
the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA and propries in the CtvFAA and propries in
the CtvFAA

to a plant to the experience of the experience o

No develop when yell related, the confines we infeature and intensive groups are noted to resume. No there are in No. No constrained Variable.

Condensational for incomment Variable.

Condensational for incomment variable in the confines of the confine

\*\*\*ANNEAN MACTIONS\*\*

The following clicially significant adverse reactions are described observer in the labeling:

\*\*Typer-markity Reactions (now Normings and Procussions (2.3)]

\*\*Lifesianto Size Societies (see Normings and Procussions (5.3)]

6.1 Clinical Trish Experience

```
The property of the property o
                     Co., In Cr. in entiring reducity right, the dosp product is not labeled with an polaric information.

2. Personan-length programmer

The following absence reactions have been identified during past supproved use of

The following absence reactions have been identified during past supproved an effect of the contract o
                                          7 DRUG INTERACTIONS
                     T BRIGO THE LEGISLATIONS LITTLE of The Suppose and Suppose as the Pharmacokhords of Other Drogs Whose administration in memorals, incapraigne, a product of propriate, is consented on the suppose as the
                               CYP3A4 Substrates
Pinocide
Clinical Impact Increases
Intervention Fosuper
Benoodicappines
Clinical Impact Increases
                     Claud Importion waster ground for opcome and opcome ano
                               chemibrany cycle.

Other
SHTD, Antagonia
SHTD, Antagonia
Chaster in the exposure of the 5-HT<sub>2</sub> antagonius (see Clinical Phermacology (22.3)).

Amountain
No drange adjunction anded
Sample conformations, granteering, distances
                                          7.2 Effect of Other Drags on the Flaremacokinetics of Fasagrephanti/perplant
Aperptant is CYPIA4 substrate for Calcul Flaremacoking (7.2%). Co-distinguisation of fusagrephan
with dupy the are influence or lackes of CYPIA4 may read in Intervended's
Table 8 Effects of Other Drags on Flaremacokinetics of Fasagrephanti/Aperplant
Table 8 Effects of Other Drags on Flaremacokinetics of Fasagrephanti/Aperplant
                     Table I Hart in Glober Deep on Parture calculates of 12 superplanel (Approximate Vinderium Swang Carlos Marinera Swang Carlos Marinera Swang Carlos Marinera Swang Carlos Marinera (Approximate Carlos Marinera Carlos Marinera (Appr
                     Chapter Advances Anneses Annes
                               Data
Animal Data
From the motoring manner constant.

12 Fronting and Marke Experiencing Protection

13 Fronting and Marke Experiencing Protection

14 Fronting and Company of the Company of
                               Photocoacting (2013).

The Printers with Printers being Integritizene.

The photocoactic form of the printer in parties to parties with mild and maken to begat in paginares.

The photocoactic form of the printer in parties of the printer in the parties of the paginary of the printer in the paginary of the paginary of
```

induced masses and vonting(CNV). Appreption has been shown in natural models to inhibit memoric induced by cytoto via central action. Annual and human pointone Enrisolon Tomography (PET) induces with apreption have shown that it crossess the blood brain hurrier and occupies brain NN<sub>2</sub> receptors. Antual and humanizables have shown that appreption angienetis brain NN<sub>2</sub> receptors. Antual and humanizables have shown that appreption angienetis the anticentic activity of the 5-HT<sub>2</sub>-

```
Indeed oransis.

Clark Enternalisation.

Trails Internalisation.

Trail
                 Amendment is a control of appropriate to term to produce a cell forms but proportion and in 12 
proportion to controlly destributes more an inclining labor, long and long The 1. 
The controlly destributes are controlled to the controlled to the controlled to the long 
Appropriate origings controlled to the controlled
                 to ...177.E.1 was descried.

In healthy young adults, aprephisar accounts for approximately 24% of the radioactivity in planes over 72 hours following a slopely on all 200-mg done of [**C-parpetrata, inflicating a substantial preserver of metabolites in the planes. Seven metabolites of aprephisar, which are only wealthy active, however, inferrited in house planes.
        Devices desirable of a singletimenous 100 mg date of [1<sup>8</sup>C<sub>2</sub>]. The Control of t
                         To this weight of the distribution of a single done of aperptine, ranging from 40 mg to 325 mg, the AUC, and C<sub>Gain</sub> are 75% and 17% higher in females as compared with males. The bull-life of aperptinents occurred a green of the compared with males and the compared and the comp
        experience by 20% however between the Table and Table 20% has been assured to the last of Table 20% has been as the Table and th
                 and 188 B model of corner is provint leading of apprint in pattern with read disease by ACC of parametelepticity active subroad dong was not significantly affects with read disease by ACC of the amendelepticity active unbound dong was not significantly affects with real impairment compared with half also applies. Heredady byte conducted or of broas after dusing bad no significant effects only pharmeteless of approximate less than 2.5 of the dross was recovered in the disease.
        Repair Separation

Fraction Separation

Fraction Separation Separa
                 ne mangin.

Predictive use information is approved for Merck Sharp & Dohne Corp., a subsidiary of Merck & Co., Inc.'s

Emend (fosaprepiated) for injection. However, due to Merck Sharp & Dohne Corp., a subsidiary of Merck &

Co., Inc.'s marketing enchanisty rights, this drug product is not labeled with that pediatric information.

Drug Interaction: Studies.
        Co. In the contribution of contribution of the complete in the factor of the disputed operation. 
In Appropriation prices are supply 1250—

of the contribution of CVFMA of the contribution of a distribution of the contribution of CVFMA of the contribution of CVFMA of the contribution of CVFMA of the contribution of the contr
        Doublemburg of the Company of the Co
mg-Bor-ng-John et selbasor he pharmochistics of decreases. As object regions (123 mg/Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-Bor-ng-B
                 using mencarious usely.

SHIT composition in chile-coloring interaction stadios, apreption did not have chiscally important effects on the phermicolitation of melanemone, garden tone, or hydrodolaserous (the active methodise of dollaremone).

Hiterat of Other Diseases the Thormacolitation of Teaserrestine/Aereptant.

Rilevajor.
        Billion Land Community of Beneral Information of State American St
        of this prepares adjustment. The office was increasined clinicity imposes.

IN Continues Land Medical Continues and present and present adjustment of President Continues and Continues 
                 Mangaroni. Apprise and incoperspirat were not generated in the Anna we, doe beams hympholiumid cell (TIX2) ensingers in so, the rat beginning DEA and brack that the Climber harmor every programmed Farming. Descriptions and the mass entermined to the Comparison of Comp
                 14 CLINICAL STUDIES
        MELINEARY STATE OF THE PROPERTY OF THE PROPERT
                         * foragrepitant for injection placebo, aprepitant capsules placebo and dexamedrancee placebo
(in the evenings on Days 3 and 4) were used to maintain blinding.
        to the eventage on Day 3 and C systems cell to make placebee and scare thinness placebee to the eventage on Day 3 and C systems cell to make thinness placebee to the cell of the placebee and the placebee to the cell of the placebee to the cell of the placebee to the pla
```

providing distinction are only the controlly recommended also. Before the abundances of the controlled also distinction and the controlled also distinction and the controlled also distinction and the controlled also distinctions are controlled as the controlled also distinctions are controlled as the region of the first and the first age of the first and the controlled as the controlled

	Day 1	Day 2	Day 3
Fosuprepitant Regimen			
Fosaprepitant for Injection	150 mg intravenously over 20 to 30 minutes approximately 30 minutes prior to chemotherapy	none	none
Oral Dexamethasone <sup>†</sup> Oral Ondametron <sup>‡</sup> Standard Therapy	12 mg 8 mg for 2 doses	none none	none
Oral Dexamethasone	20 mg	none	10000
Oral Ordansetron <sup>2</sup>	8 mg for 2 doses	8 mg twice daily	8 mg twice daily

binding.

The contribution was administrated 30 minutes prior in chemistracy research on Day 1.7 to 12 mg door reflects a disage adjustment to accound for a denig interaction with the Prospergiona for injection regimes (see Citatic Funncessing (27.2)).

The first condumerous done was administrated 30 to 60 minutes parties of the other parties of the condumerous done was administrated for some other condumerous done. The prior of the condumerous done was administrated for some other parties of the condumerous done. The prior of prior of prior is described by the condumerous done. The prior of prior of prior is described as an accomming administrate during the condumerous described and the

Foxaprepitant for Injection Standard Therapy					
ENDPOINTS	Regimen (N = 502)* %	Regimen (N = 493)* %	p. Value	Treatment Difference (95% CI	
PRIMARYENDPOINT Complete Response <sup>†</sup>					
Delayed phase <sup>2</sup>	78.9	68.5	< 0.001	10.4 (5.1, 15.9)	

\*N: Number of patients included in the intention to treat population.

\*Complete Response = no vorsiting and no use of rescue therapy.

\*Delayed phase = 25 to 120 hours post-initiation of chemotherapy.

NDC43598-948-111 vial per cartos.

Stronge Possper-plant for injection vials must be refrigerated, since at  $2^{\infty}C - 8^{\infty}C(38^{\circ}F - 46^{\circ}F)$ . The recommissed final drug solution is suble for 24 hours at ambient commissperature (at or below  $22^{\circ}C(7^{\circ}F)$ ).

DATATIN COUNTAIN ON NORMATION

Abote the pattern was the ThAppeared placeful ability (Others Mormation).

Disputation that the Countain of the

Drug Interactions
Advise patients to discuss all medications they are taking, including other prescription, nonprescription medication or herbal products(see Contraindications (4), Warrings and Precautions (5.1)).
Warfarier.

Here Auditor Control C

watered by the property of the

After the growthest fraction and management of the production of the production of production of the production of the production of production of the p





FOSAPREPITANT					
fosaprepitant injection, powd	er, lyophikard, for solution				
Product Information					
Predact Type	HEMAN PRENCHPTION DRUG	Brm Code (Neurce)	NDC-43589-948		
Raute of Administration	DITEASENDUS				

r.								
	Fanaporphiant Disorghaniar (UND DESPMETHAX) (Aperphian UND DESIMELY		BEETO)				250 mg in 1 m	
In	scrive lagredies							
		Ingredient Name			Strength			
	rists Redison (UNI)				5.4 mg in 5 mil.			
Anhydrous Laviere (UNIS SEVELIBERIE)					375 mg in 5 ml.			
Polysochair 80 (CNS-6027792/2010)				2	ing in l	mi.		
	lium Hydraxide (U)							
H <sub>2</sub>	Brankfartis Artid (US)	n-qrrrrssacs)						
ij	Item Code	Package Description		ing Star	t Dute	Mark	ting End Dr	
22	ckaging							
X)s	DC-03588-948-11	I is I CARTON	07/05/200	00				
ı i		Leaf, in 1 VSAL: Type O: No. a Combination Product						
M	arketing Info	rmation						
Marketing Category		Application Number or Menograph Citation	Marketing Start Date		ori Date	Marketing End Da		
	DA	ANDAJOSSES	07/09/2020					
AN								
AN								
AN								
	heler - n. m.u	y's Laboratories Inc., (882311887)						